natgillin/translations-raw huggingface dataset:
Treated subjects (n = 201) had a median age of 56 years (range: 24 to 70); 70% of the subjects were male; 87% were White; 3% were Black; 9% were Hispanic or Latino; mean body mass index was 29 kg/m2 (range: 19 to 44 kg/m2); 73% had baseline HCV RNA levels greater than 6 log10 IU/mL; 34% had cirrhosis; 63% had HCV genotype 3; 75% were prior relapsers.
Medijan dobi liječenih ispitanika (n = 201) bio je 56 godina (raspon: 24 do 70); 70% ispitanika bili su muškarci; 87% bili su bijelci; 3% bili su crnci; 9% bili su hispano- ili latino-porijekla; srednja vrijednost indeksa tjelesne mase bila je 29 kg/m2 (raspon: 19 do 44 kg/m2); 73% imalo je početnu razinu HCV RNK veću od 6 log10 IU/ml; 34% imalo je cirozu; 63% imalo je HCV-genotip 3; 75% je prethodno imalo relaps.
Treated subjects (n = 278) had a median age of 54 years (range: 21 to 75); 54% of the subjects were male; 91% were White; 5% were Black; 11% were Hispanic or Latino; mean body mass index was 28 kg/m2 (range: 18 to 53 kg/m2); 70% had baseline HCV RNA levels greater than 6 log10 IU/mL; 16% had cirrhosis; 49% had HCV genotype 3.
Medijan dobi liječenih ispitanika (n = 278) bio je 54 godine (raspon: 21 do 75); 54% ispitanika bili su muškarci; 91% bili su bijelci, 5% bili su crnci; 11% bili su hispano- ili latino-porijekla; srednja vrijednost indeksa tjelesne mase bila je 28 kg/m2 (raspon: 18 to 53 kg/m2); 70% imalo je početne razine HCV RNK veće od 6 log10 IU/ml; 16% imalo je cirozu; 49% imalo je HCV-genotip 3.
Treated subjects (n = 327) had a median age of 54 years (range: 19 to 70); 64% of the subjects were male; 79% were White; 17% were Black; 14% were Hispanic or Latino; mean body mass index was 29 kg/m2 (range: 18 to 56 kg/m2); 78% had baseline HCV RNA greater than 6 log10 IU/mL; 17% had cirrhosis; 89% had HCV genotype 1 and 11% had HCV genotype 4, 5 or 6.
Medijan dobi liječenih ispitanika (n = 327) bio je 54 godine (raspon: 19 do 70); 64% ispitanika bili su muškarci; 79% bili su bijelci, 17% bili su crnci; 14% bili su hispano ili latino-porijekla; srednja vrijednost indeksa tjelesne mase iznosila je 29 kg/m2 (raspon: 18 do 56 kg/m2); 78% imalo je početni HCV RNK veći od 6 log10 IU/ml; 17% imalo je cirozu; 89% imalo je HCV-genotip 1 i 11% je imalo HCV-genotip 4, 5 ili 6.
Treated subjects (n = 419) had a median age of 51 years (range: 19 to 74); 60% of the subjects were male; median body mass index was 25 kg/m2 (range: 17 to 44 kg/m2); the mean baseline HCV RNA level was 6.4 log10 IU/mL; 21% had cirrhosis; 78% had HCV genotype 3; 65% were prior relapsers.
Medijan dobi liječenih ispitanika (n = 419) bio je 51 godina (raspon: 19 do 74); 60% ispitanika bili su muškarci; medijan indeksa tjelesne mase iznosio je 25 kg/m2 (raspon: 17 do 44 kg/m2); srednja vrijednost početne razine HCV RNK bila je 6,4 log10 IU/ml; 21% imalo je cirozu; 78% imalo je HCV- genotip 3; 65% je prethodno imalo relaps.
Treated subjects (n = 499) had a median age of 50 years (range: 19 to 77); 66% of the subjects were male; 87% were White; 3% were Black; 14% were Hispanic or Latino; mean body mass index was 28 kg/m2 (range: 17 to 52 kg/m2); 57% had baseline HCV RNA levels greater than 6 log10 IU/mL; 20% had cirrhosis; 72% had HCV genotype 3.
Medijan dobi liječenih ispitanika (n = 499) bio je 50 godina (raspon: 19 do 77); 66% ispitanika bili su muškarci; 87% bili su bijelci, 3% bili su crnci; 14% bili su hispano- ili latino-porijekla; srednja vrijednost indeksa tjelesne mase bila je 28 kg/m2 (raspon: 17 do 52 kg/m2); 57% je imalo početnu razinu HCV RNK veću od 6 log10 IU/ml; 20% imalo je cirozu; 72% imalo je HCV genotip 3.
Treated subjects (N = 63) had a median age of 51 years (range: 31 to 69); 24% of subjects were Black; 19% of subjects had compensated cirrhosis; 67% of subjects were HCV treatment-naïve; 33% of subjects had failed prior treatment with pegIFN/RBV; 89% of subjects had HCV genotype 1a infection.
Medijan dobi liječenih ispitanika (N = 63) bio je 51 godina (raspon od 31 do 69), 24% su bili crnci, 19% ispitanika imalo je kompenziranu cirozu, 67% nije bilo prethodno liječeno, 33% ispitanika bilo je prethodno neuspješno liječeno pegIFN/RBV-om, 89% ispitanika imalo je infekciju HCV-om genotipa 1a.
Treated subjects (N=179) had a median age of 57 years (range: 26 to 70); 35.2% were prior pegIFN/RBV null responders; 28.5% were prior pegIFN/RBV partial responders, and 36.3% were prior pegIFN/RBV relapsers; 54.2% were male; 3.9% were Black; 12.8% had a history of depression or bipolar disorder; 87.7% had baseline HCV RNA levels of at least 800,000 IU/mL; 17.9% had portal fibrosis (F2) and 14.0% had bridging fibrosis (F3).
Medijan dobi liječenih ispitanika (N=179) iznosio je 57 godina (raspon: 26 do 70); 35,2% nije ostvarilo odgovor na prethodno liječenje kombinacijom pegIFN/RBV, 28,5% ostvarilo je djelomičan odgovor na prethodno liječenje kombinacijom pegIFN/RBV, a 36,3% doživjelo je relaps nakon prethodnog liječenja kombinacijom pegIFN/RBV; 54,2% ispitanika bili su muškarci; 3,9% bili su crnci; 12,8% imalo je depresiju ili bipolarni poremećaj u anamnezi; 87,7% imalo je početne razine HCV RNK od najmanje 800 000 IU/ml; 17,9% imalo je portalnu fibrozu (F2), a 14,0% premoštavajuću fibrozu (F3).
Treated subjects (N=179) had a median age of 57 years (range: 26 to 70); 35.2% were prior pegIFN/RBV null responders; 28.5% were prior pegIFN/RBV partial responders; and 36.3% were prior pegIFN/RBV relapsers; 54.2% were male; 3.9% were Black; 21.8% had a body mass index of at least 30 kg/m2; 12.8% had a history of depression or bipolar disorder; 90.5% had IL28B non-CC genotype; 87.7% had baseline HCV RNA levels of at least 800,000 IU/mL; 17.9% had portal fibrosis (F2) and 14.0% had bridging fibrosis (F3).
Medijan dobi liječenih ispitanika (N=419) iznosio je 50 godina (raspon: 19 do 70); 45,8% bili su muškarci; 4,8% bili su crnci; 16,5% imalo je indeks tjelesne mase od najmanje 30 kg/m2; 9,3% imalo je depresiju ili bipolarni poremećaj u anamnezi; 79,0% imalo je IL28B non-CC genotip; 73,3% imalo je početnu razinu HCV RNK od najmanje 800 000 IU/ml; 20,3% imalo je portalnu fibrozu (F2), a 10,0% premoštavajuću fibrozu (F3).
Treated subjects (N=305) had a median age of 54 years (range: 19 to 70); 65.2% were male; 11.8% were Black; 20.7% had a history of depression or bipolar disorder; 86.6% had baseline HCV RNA levels of at least 800,000 IU/mL; 18.4% had portal fibrosis (F2) and 17.7% had bridging fibrosis (F3).
Medijan dobi liječenih ispitanika (N=305) iznosio je 54 godine (raspon: 19 do 70); 65,2% bili su muškarci; 11,8% bili su crnci; 20,7% imalo je depresiju ili bipolarni poremećaj u anamnezi; 86,6% imalo je početne razine HCV RNK od najmanje 800 000 IU/ml; 18,4% imalo je portalnu fibrozu (F2), a 17,7% premoštavajuću fibrozu (F3).
Treated subjects (N=380) had a median age of 58 years (range: 21 to 71); 42.1% were treatment-naïve, 36.1% were prior pegIFN/RBV null responders; 8.2% were prior pegIFN/RBV partial responders, 13.7% were prior pegIFN/RBV relapsers; 70.3% were male; 3.2% were Black; 14.7% had platelet counts of less than 90 x 109/L; 49.7% had albumin less than 40 g/L; 86.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 24.7% had a history of depression or bipolar disorder; 68.7% had HCV genotype 1a infection, 31.3% had HCV genotype 1b infection.
Medijan dobi liječenih ispitanika (N=380) iznosio je 58 godina (raspon: 21 do 71); 42,1% prethodno nije bilo liječeno; 36,1% nije ostvarilo odgovor na prethodno liječenje kombinacijom pegIFN/RBV; 8,2% ostvarilo je djelomičan odgovor na prethodno liječenje kombinacijom pegIFN/RBV; 13,7% doživjelo je relaps nakon prethodnog liječenja kombinacijom pegIFN/RBV; 70,3% ispitanika bili su muškarci; 3,2% bili su crnci; 14,7% imalo je broj trombocita manji od 90 x 109/l, 49,7% imalo je razinu albumina manju od 40 g/l; 86,1% imalo je početne razine HCV RNK od najmanje 800 000 IU po ml; 24,7% imalo je depresiju ili bipolarni poremećaj u anamnezi; 68,7% imalo je infekciju HCV-om genotipa 1a; 31,3% imalo je infekciju HCV-om genotipa 1b.
Treated subjects (N=380) had a median age of 58 years (range: 21 to 71); 42.1% were treatment-naïve, 36.1% were prior pegIFN/RBV null responders; 8.2% were prior pegIFN/RBV partial responders, 13.7% were prior pegIFN/RBV relapsers; 70.3% were male; 3.2% were Black; 28.4% had a body mass index of at least 30 kg/m2; 14.7% had platelet counts of less than 90 x 109/L; 49.7% had albumin less than 40 g/L; 86.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 81.8% had IL28B non-CC genotype; 24.7% had a history of depression or bipolar disorder; 68.7% had HCV genotype 1a infection, 31.3% had HCV genotype 1b infection.
Medijan dobi liječenih ispitanika (N=394) iznosio je 54 godine (raspon: 19 do 71); 49,0% nije ostvarilo odgovor na prethodno liječenje kombinacijom pegIFN/RBV, 21,8% ostvarilo je djelomičan odgovor na prethodno liječenje kombinacijom pegIFN/RBV, a 29,2% doživjelo je relaps nakon prethodnog liječenja kombinacijom pegIFN/RBV; 57,6% ispitanika bili su muškarci; 8,1% bili su crnci; 19,8% imalo je indeks tjelesne mase od najmanje 30 kg/m2; 20,6% imalo je depresiju ili bipolarni poremećaj u anamnezi; 89,6% imalo je IL28B non-CC genotip; 87,1% imalo je početnu razinu HCV RNK od najmanje 800 000 IU po ml; 17,8% imalo je portalnu fibrozu (F2), a 14,5% premoštavajuću fibrozu (F3); 58,4% imalo je infekciju HCV-om genotipa 1a; 41,4% imalo je infekciju HCV-om genotipa 1b.
Treated subjects (N=394) had a median age of 54 years (range: 19 to 71); 49.0% were prior pegIFN/RBV null responders; 21.8/% were prior pegIFN/RBV partial responders, and 29.2% were prior pegIFN/RBV relapsers; 57.6% were male; 8.1% were Black; 20.6% had a history of depression or bipolar disorder; 87.1% had baseline HCV RNA levels of at least 800,000 IU per mL; 17.8% had portal fibrosis (F2) and 14.5% had bridging fibrosis (F3); 58.4% had HCV genotype 1a infection; 41.4% had HCV genotype 1b infection.
Medijan dobi liječenih ispitanika (N=394) iznosio je 54 godine (raspon: 19 do 71); 49,0% nije ostvarilo odgovor na prethodno liječenje kombinacijom pegIFN/RBV, 21,8% ostvarilo je djelomičan odgovor na prethodno liječenje kombinacijom pegIFN/RBV, a 29,2% doživjelo je relaps nakon prethodnog liječenja kombinacijom pegIFN/RBV; 57,6% ispitanika bili su muškarci; 8,1% bili su crnci; 20,6% imalo je depresiju ili bipolarni poremećaj u anamnezi; 87,1% imalo je početnu razinu HCV RNK od najmanje 800 000 IU po ml; 17,8% imalo je portalnu fibrozu (F2), a 14,5% premoštavajuću fibrozu (F3); 58,4% imalo je infekciju HCV-om genotipa 1a; 41,4% imalo je infekciju HCV-om genotipa 1b.
Treated subjects (N=394) had a median age of 54 years (range: 19 to 71); 49.0% were prior pegIFN/RBV null responders; 21.8/% were prior pegIFN/RBV partial responders; and 29.2% were prior pegIFN/RBV relapsers; 57.6% were male; 8.1% were Black; 19.8% had a body mass index of at least 30 kg/m2; 20.6% had a history of depression or bipolar disorder; 89.6% had IL28B non-CC genotype; 87.1% had baseline HCV RNA levels of at least 800,000 IU per mL; 17.8% had portal fibrosis (F2) and 14.5% had bridging fibrosis (F3); 58.4% had HCV genotype 1a infection; 41.4% had HCV genotype 1b infection.
Medijan dobi liječenih ispitanika (N=631) iznosio je 52 godine (raspon: 18 do 70); 54,5% bili su muškarci; 5,4% bili su crnci; 16,2% imalo je indeks tjelesne mase od najmanje 30 kg/m2; 15,2% imalo je depresiju ili bipolarni poremećaj u anamnezi; 69,3% imalo je IL28B non-CC genotip; 79,1% imalo je početne razine HCV RNK od najmanje 800 000 IU/ml; 15,4% imalo je portalnu fibrozu (F2), a 8,7% premoštavajuću fibrozu (F3); 67,7% imalo je infekciju HCV-om genotipa 1a; 32,3% imalo je infekciju HCV-om genotipa 1b.
Treated subjects (N=419) had a median age of 50 years (range: 19 to 70), 45.8% were male; 4.8% were Black; 9.3% had a history of depression or bipolar disorder; 73.3% had baseline HCV RNA of at least 800,000 IU/mL; 20.3% had portal fibrosis (F2) and 10.0% had bridging fibrosis (F3).
Medijan dobi liječenih ispitanika (N=419) iznosio je 50 godina (raspon: 19 do 70); 45,8% bili su muškarci; 4,8% bili su crnci;; 9,3% imalo je depresiju ili bipolarni poremećaj u anamnezi; 73,3% imalo je početnu razinu HCV RNK od najmanje 800 000 IU/ml; 20,3% imalo je portalnu fibrozu (F2), a 10,0% premoštavajuću fibrozu (F3).
Treated subjects (N=631) had a median age of 52 years (range: 18 to 70); 54.5% were male; 5.4% were Black; 15.2% had a history of depression or bipolar disorder; 79.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 15.4% had portal fibrosis (F2) and 8.7% had bridging fibrosis (F3); 67.7% had HCV genotype 1a infection; 32.3% had HCV genotype 1b infection.
Medijan dobi liječenih ispitanika (N=631) iznosio je 52 godine (raspon: 18 do 70); 54,5% bili su muškarci; 5,4% bili su crnci; 15,2% imalo je depresiju ili bipolarni poremećaj u anamnezi; 79,1% imalo je početne razine HCV RNK od najmanje 800 000 IU/ml; 15,4% imalo je portalnu fibrozu (F2), a 8,7% premoštavajuću fibrozu (F3); 67,7% imalo je infekciju HCV-om genotipa 1a; 32,3% imalo je infekciju HCV-om genotipa 1b.
treated with roflumilast.
31.03.2021.
treating
liječnika)
treating a fracture that is related to a disease such as Paget’s disease or cancer.
liječenje frakture koje je povezano s bolešću, poput Pagetove bolesti ili raka.
Treating anaemia with related symptoms in adult cancer patients receiving chemotherapy
Liječenje anemije s pridruženim simptomima u odraslih bolesnika s rakom koji primaju kemoterapiju.
Treating diarrhoea early is important (see section 4);
Rano liječenje proljeva je važno (vidjeti dio 4);
Treating people donating their own blood before surgery.
Liječenje bolesnika koji doniraju vlastitu krv prije operacije.
Treating physician should always expel excess volume of solution according to instructions under the section 6.6.
Nadležni liječnik uvijek treba potisnuti višak volumena otopine prema uputama u dijelu 6.6.
Treating symptomatic anaemia caused by chronic kidney disease (renal anaemia) in patients on dialysis, or not yet on dialysis.
Liječenje simptomatske anemije uzrokovane kroničnom bolesti bubrega (bubrežna anemija) u bolesnika na dijalizi ili u bolesnika koji još nisu na dijalizi.
Treatme nt in patients with acute STEMI
Terapija bolesnika s akutnim STEMI
Treatmen t in patients with acute STEMI
Terapija bolesnika s akutnim STEMI
Treatmen t in patients with unstable angina and non- Q-wave MI
Terapija bolesnika s nestabilno m anginom pektoris i IM bez Q- zupca
treatment
liječenja
Treatment
Liječenje i
Treatment
Liječenje MP
Treatment
Liječenje:
treatment
limfoma
Treatment
Razlika
Treatment (LEVP 2006-1): The proportion of HAE attacks achieving unequivocal relief of the defining symptom within 4 hours after Cinryze treatment was comparable between the 22 children enrolled (age range: 2-17) and adults, with 89% and 86% of attacks achieving relief, respectively.
Liječenje (LEVP 2006-1): Udio napadaja HAE kod kojih se postiglo vidljivo povlačenje glavnog simptoma u roku od 4 sata nakon liječenja lijekom Cinryze bio je usporediv između 22 uključene djece (raspon dobi: 2-17) i odraslih, s time da se povlačenje simptoma postiglo u 89% odnosno 86% napadaja.
treatment (see
mješovito oštećenje jetre)11
treatment (see section
početku liječenja (vidjeti dio 4.4)
treatment (see section
trombozu) (vidjeti
treatment (see section 4.4)
početku liječenja (vidjeti dio 4.4)
Treatment - Invasive Aspergillosis Study 0041
Liječenje - invazivna aspergiloza Ispitivanje 0041
Treatment adherence rates for the integrated Phase 3 studies were: 67% NB vs.
Stope pridržavanja liječenja za integrirana ispitivanja faze 3 su bile: 67 % NB naspram 74 % placebo
Treatment after LH surge but before LH peak
Primjena nakon postizanja vršne koncentracije LH
Treatment against Isospora should aim to minimize the shedding of oocysts into the environment, thereby reducing the risk for reinfection in groups/kennels with known and recurring Isospora infections.
Tretiranje protiv Isospora ima za cilj smanjivanje izlučivanja oocista u okoliš, na taj način se smanjuje rizik od ponovne pojave u uzgoju/uzgajivačnici i rekurentne invazije Isosporom.
Treatment and
Liječenje i
Treatment and control of gastro-intestinal nematodes in pigs infected with:
Liječenje i kontrola gastrointestinalnih nematoda u svinja zaraženih s:
Treatment and control of gastro-intestinal nematodes in pigs infected with:
Za liječenje i kontrolu gastro-intestinalnih nematoda u svinja zaraženih s:
Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis sensitive to tulathromycin.
Liječenje i metafilaksa bolesti dišnih organa goveda (BRD) uzrokovanih bakterijama Mannheimia haemolytica, Pasteurella multocida, Histophilus somni i mikoplazmom Mycoplasma bovis koje su osjetljive na tulatromicin.
Treatment and metaphylaxis of bovine respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis sensitive to tulathromycin.
Liječenje i metafilaksa bolesti dišnih organa goveda (BRD) uzrokovanih bakterijama Mannheimia haemolytica, Pasteurella multocida, Histophilus somni i mikoplazmom Mycoplasma bovis koje su osjetljive na tulatromicin.
Treatment and metaphylaxis of swine dysentery in herds, caused by Brachyspira hyodysenteriae, where the disease has been diagnosed.
Liječenje i metafilaksa dizenterije prouzročene bakterijom Brachyspira hyodysenteriae u uzgojima u kojima je bolest.
Treatment and metaphylaxis of swine dysentery in herds, where the disease has been diagnosed.
Liječenje i metafilaksa dizenterije u uzgojima u kojima je bolest dijagnosticirana.
Treatment and metaphylaxis of swine dysentery, caused by Brachyspira hyodysenteriae in herds where the disease has been diagnosed.
Liječenje i metafilaksa dizenterije prouzročene bakterijom Brachyspira hyodysenteriae u uzgojima u kojima je bolest dijagnosticirana.
Treatment and metaphylaxis of swine dysentery, caused by Brachyspira hyodysenteriae in herds where the disease has been diagnosed.
Liječenje i metafilaksa dizenterije prouzročene bakterijom Brachyspira hyodysenteriae u uzgojima u kojima je bolest.
Treatment and metaphylaxis of swine enzootic pneumonia caused by susceptible strains of Mycoplasma hyopneumoniae in pigs.
Liječenje i metafilaksa enzootske pneumonije svinja prouzročene osjetljivim sojevima bakterije Mycoplasmahyopneumoniae u svinja.
Treatment and metaphylaxis of swine enzootic pneumonia caused by susceptible strains of Mycoplasma hyopneumoniae.
Liječenje i metafilaksa enzootske pneumonije svinja prouzročene osjetljivim sojevima bakterije Mycoplasma hyopneumoniae u svinja.
Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica and Haemophilus parasuis sensitive to tildipirosin.
Liječenje i metafilaksa dišnih bolesti svinja povezanih s Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica i Haemophilus parasuis osjetljivih na tildipirosin.
Treatment and metaphylaxis of swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica sensitive to tulathromycin.
Liječenje i metafilaksa respiratornih infekcija u svinja vezanih uz bakterije i mikoplazmu: Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae,Haemophilus parasuis i Bordetella bronchiseptica osjetljivih na tulatromicin.
Treatment and monitoring recommendations*
Preporuke za liječenje i nadzor
Treatment and pre-procedure prevention of angioedema attacks in adults and adolescents 12 to 17 years old with hereditary angioedema (HAE).
Liječenje i prevencija napadaja angioedema prije zahvata u odraslih i adolescenata u dobi od 12 do 17 godina s hereditarnim angioedemom (HAE).
Treatment and prevention of flea infestation (Ctenocephalides canis and C. felis.).
Liječenje i prevencija infestacije buhama (Ctenocephalides canis i C. felis).
Treatment and prevention of flea infestation (Ctenocephalides felis).
Liječenje i sprečavanje infestacije buha ( Ctenocephalides felis)
Treatment and prevention of flea infestation (Ctenocephalides felis).
Liječenje i sprečavanje infestacije buha (Ctenocephalides felis)
Treatment and prevention of flea infestation (Ctenocephalides felis).
Liječenje i sprečavanje infestacije buhama ( Ctenocephalides felis).
Treatment and prevention of flea infestation when concurrent prevention of heartworm disease and/or concurrent treatment of nematode infections is indicated.
Za liječenje i prevenciju infestacija buhama kada je indicirana istovremena prevencija dirofilarioze, tj. bolesti srčanog crva i/ili liječenje gastrointestinalnih infestacija uzrokovanih oblićima.
Treatment and prevention of flea infestations caused by Ctenocephalides spp. for one month following a single administration.
Liječenje i prevencija infestacija buhama uzrokovanih s Ctenocephalides spp. tijekom mjesec dana nakon jednokratne primjene.
Treatment and prevention of flea infestations caused by Ctenocephalides spp. for one month following a single administration.
Terapija i prevencija infestacije buhama uzrokovane Ctenocephalides spp. tijekom mjesec dana nakon jednokratne primjene.
Treatment and prevention of infestations by fleas (Ctenocephalides felis).
Liječenje i prevencija infestacije buhama (Ctenocephalides felis).
Treatment and prevention of infestations by ticks (Ixodes ricinus).
Liječenje i prevencija infestacije krpeljima (Ixodes ricinus).
Treatment and prevention of infestations with fleas and ticks.
Liječenje i prevencija infestacije buhama i krpeljima.
Treatment and prevention of swine enzootic pneumonia.
Liječenje i prevencija svinjske enzootske pneumonije.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Liječenje i profilaksa krvarenja u bolesnika s hemofiijom A (urođeni nedostatak faktora VIII).
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Liječenje i profilaksa krvarenja kod pacijenata s hemofilijom B (prirođeni nedostatak faktora IX).
Treatment arm
Terapijska skupina
Treatment arm PFS rate at PFS rate at HR
Liječena skupina Stopa PFS-a u Stopa PFS-a u HR
Treatment arms (n)
Terapijske skupine (n)
Treatment at IC90 for 72 hours resulted in a 1-log10 drop in replicon RNA.
Liječenje pri IC90 tijekom 72 sata rezultiralo je padom RNK replikona od 1–log10.
Treatment at the first signs of diarrhoea is important. if you develop skin rash.
Liječenje proljeva u početnoj fazi je važno. ako razvijete osip na koži.
Treatment before LH surge
Primjena prije početka LH vala
Treatment benefit perception was measured by the Patient Global Impression of Change (PGIC) questionnaire.
Percepcija koristi liječenja mjerena je upitnikom o bolesnikovom općem dojmu o promjeni (eng.
Treatment can be given as a once daily dose or alternatively the daily dose may be split into two administrations – one in the morning and one in the evening.
Terapija se može primjenjivati jedanput na dan ili se dnevna doza može podijeliti u dvije primjene – ujutro i navečer.
Treatment can be given as a once daily dose or alternatively the daily dose may be split into two administrations – one in the morning and one in the evening.
Terapija se može primjenjivati kao doza koja se daje jednom na dan, ili se dnevna doza može podijeliti u dvije primjene – jedna ujutro, a jedna navečer.
Treatment can be interrupted if platelet counts become too high.
Liječenje se može prekinuti ako broj trombocita postane previsok.
Treatment can be maintained up to 96 hours or until the underlying oxygen desaturation has resolved and the neonate is ready to be weaned from INOmax therapy.
Liječenje može trajati do 96 sati ili dok se ne riješi stanje koje je uzrokovalo desaturaciju kisikom te dok novorođenče ne bude spremno odvikavanje od liječenja INOmax-om.
Treatment can be repeated once a month.
Tretiranje se ponavlja jednom mjesečno.
Treatment can be resumed at the discretion of the treating physician.
Liječenje se može nastaviti ako tako odluči nadležni liječnik.